Article
Medicine, General & Internal
Xiaowei Tang, Liang Shi, Zhenyu Zhao, Jun Wang, Rui Yang, Yue Huang, Jun Tang, Zhengguo Chen, Feng Wang
Summary: This study aimed to evaluate the clinical value of F-18-FDG PET/CT for the early diagnosis of RAIR-DTC and high-risk DTC. The results showed that F-18-FDG PET/CT has good sensitivity and specificity for identifying RAIR, and the tumor/liver ratio is a useful parameter.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hao Fu, Jie Fu, Jingxiong Huang, Yizhen Pang, Haojun Chen
Summary: Ga-68-FAPI is a promising alternative to F-18-FDG for detecting tumor recurrence and metastases in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), showing a better signal-to-background ratio, especially for detecting small pulmonary metastases. It can also be used for guiding FAP-targeted radionuclide therapy.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Endocrinology & Metabolism
Myat Han Soe, Janet M. Chiang, Robert R. Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu
Summary: Patients with radioactive iodine refractory metastatic differentiated thyroid cancer have a poor prognosis. This study aimed to characterize patients with non-iodine-avid disease at diagnosis. The results showed that non-iodine-avid disease is highly prevalent in DTC patients with BVL cancers, particularly with BRAF (V600E) and TERT promoter mutations, and is associated with older age.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Oncology
Zohreh Maghsoomi, Zahra Emami, Ramin Malboosbaf, Mojtaba Malek, Mohammad E. Khamseh
Summary: PRRT treatment shows promising biochemical and objective responses in patients with advanced RR-DTC and metastatic MTC. Although some patients experience side effects and deaths, overall efficacy is favorable.
Article
Endocrinology & Metabolism
Jinyan Chai, Ruiguo Zhang, Wei Zheng, Guizhi Zhang, Qiang Jia, Jian Tan, Zhaowei Meng, Renfei Wang
Summary: This study evaluated the predictive value of clinical and pathological characteristics for metastatic RAIR-DTC, finding that factors such as age, extrathyroid invasion, gene mutations, and response to RIT could predict the risk of RAIR-DTC in both TgAb-negative and TgAb-positive patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Chantal A. Lebbink, Lisa H. de Vries, Inne H. M. Borel Rinkes, Arthur J. A. T. Braat, Rachel S. van Leeuwaarde, Lutske Lodewijk, Mark J. C. van Treijen, Menno R. Vriens, Gerlof D. Valk, Hanneke M. van Santen, Bart de Keizer
Summary: This study demonstrates the potential usefulness of FDG PET/CT in detecting persistent or recurrent DTC in patients with low detectable thyroglobulin levels. However, a negative result on FDG PET/CT does not exclude the possibility of DTC, necessitating further investigations.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Cristiane J. Gomes-Lima, Leila Shobab, Di Wu, Dorina Ylli, Athanasios Bikas, Matthew McCoy, Rebecca Feldman, Wen Lee, Sarika N. Rao, Kirk Jensen, Vasily Vasko, Luiz Claudio Castro, Jacqueline Jonklaas, Leonard Wartofsky, Kenneth D. Burman
Summary: A study compared the molecular profiles of paired tumor specimens from patients with radioiodine refractory DTC, revealing heterogeneity in genetic alterations between primary and metastatic lesions, which may help explain varied responses to therapeutic intervention.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Pharmacology & Pharmacy
Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, Shenghai Xing
Summary: This study evaluated the cost-effectiveness of apatinib and cabozantinib for RAIR-DTC from the perspective of the Chinese healthcare system. The results showed that apatinib is cost-effective compared to placebo, while cabozantinib may not be cost-effective and a reduction in price is warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Wei Chen, Yu Kun Luo, Ying Zhang, Qing Song, Jie Tang
Summary: The study demonstrated that ultrasound-guided I-125 seed implantation is safe and effective in treating RR-DTC, serving as an effective supplement for the comprehensive treatment of thyroid cancer.
Article
Pharmacology & Pharmacy
Shuchun You, Jinshun Zha, Long Xie, Tingyin Jiang
Summary: The purpose of this study was to investigate the prognostic value of serum-stimulated thyroglobulin (ps-Tg) before the first 131I therapy in patients with metastatic radioactive iodine-refractory differentiated thyroid cancer (RR-DTC). The results showed that ps-Tg was an independent risk factor for predicting the occurrence of RR-DTC, which can be helpful in predicting the occurrence of RR-DTC, determining the best time to start treatment, and making individualized treatment decisions.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Emilia Zampella, Michele Klain, Leonardo Pace, Alberto Cuocolo
Summary: The standard treatment for differentiated thyroid cancer usually involves surgery and iodine-131 treatment, with follow-up including monitoring of serum thyroglobulin levels, neck ultrasound, and whole-body scans. PET/CT plays a crucial role in evaluating patients, especially high-risk and metastatic cases.
DIAGNOSTIC AND INTERVENTIONAL IMAGING
(2021)
Article
Medicine, General & Internal
Elisa Lodi Rizzini, Andrea Repaci, Elena Tabacchi, Lucia Zanoni, Valentina Vicennati, Ottavio Cavicchi, Uberto Pagotto, Alessio Giuseppe Morganti, Stefano Fanti, Fabio Monari
Summary: This study aimed to evaluate the role of 18F-FDG PET/CT in the clinical management of RAI-R-DTC and confirmed its obviation of further unnecessary RAIT. Results showed that among 53 patients, approximately half had a positive 18F-FDG PET/CT scan, leading to different therapeutic approaches, with significant associations found between metabolic response and final disease response evaluation.
Article
Radiology, Nuclear Medicine & Medical Imaging
Di Wu, Donika Plyku, Kanchan Kulkarni, Carlos Garcia, Frank Atkins, Eshetu Tefera, Kenneth D. Burman, Leonard Wartofsky, Douglas Van Nostrand
Summary: This study aimed to determine the optimal timing for I-124 PET/CT imaging in detecting locoregional and/or distant metastases of thyroid cancer. Dual-time-point imaging was found to be superior to single-time-point imaging, with the 48-hour scan showing the highest lesion detection rate visually and the highest ACR(mean)/AA quantitatively.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Endocrinology & Metabolism
Yan-Song Lin, Hui Yang, Yong Ding, Yi-Zhuang Cheng, Feng Shi, Jian Tan, Zhi-Yong Deng, Zhen-Dong Chen, Rong-Fu Wang, Qing-Hai Ji, Rui Huang, Lin-Fa Li
Summary: The study evaluated the efficacy and safety of the new multikinase inhibitor donafenib in treating locally advanced or metastatic RAIR-DTC. Both 200mg and 300mg doses of donafenib showed similar efficacy in terms of objective response rate, with the 300mg dose demonstrating a trend towards longer progression-free survival and more tumor shrinkage. The most common grade 3 treatment-related adverse events were palmar-plantar erythrodysesthesia and hypertension.
Review
Oncology
Vincenzo Marotta, Maria Grazia Chiofalo, Francesca Di Gennaro, Antonio Daponte, Fabio Sandomenico, Paolo Vallone, Luciana Costigliola, Gerardo Botti, Franco Ionna, Luciano Pezzullo
Summary: Kinase-inhibitors sorafenib and lenvatinib have shown efficacy in iodine-refractory differentiated thyroid cancer, but there is inadequate evidence for a clear risk-benefit balance and optimal treatment sequence. Indirect comparisons suggest sorafenib may have milder toxicity, while lenvatinib is supported as a second-line option for pre-treated patients. More research is needed to establish a structured therapeutic algorithm for the use of KIs in this type of cancer.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Otorhinolaryngology
Cristina P. Rodriguez, Renato G. Martins, Christina Baik, Laura Q. Chow, Rafael Santana-Davila, Bernardo H. Goulart, Sylvia Lee, Keith D. Eaton
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2018)
Article
Oncology
Margaret K. Guerriero, Mary W. Redman, Kelsey K. Baker, Renato G. Martins, Keith Eaton, Laura Q. Chow, Rafael Santana-Davila, Christina Baik, Bernardo H. Goulart, Sylvia Lee, Cristina P. Rodriguez
Article
Oncology
Gentry T. King, Keith D. Eaton, Brandon R. Beagle, Christopher J. Zopf, Gilbert Y. Wong, Heike I. Krupka, Steven Y. Hua, Wells A. Messersmith, Anthony B. El-Khoueiry
INVESTIGATIONAL NEW DRUGS
(2018)
Editorial Material
Oncology
Annika M. Gustafson, Deborah J. Goldfrank, William A. Dunson, Daniel L. Mulkerin, Rebecca L. Caires, Keith D. Eaton
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2018)
Letter
Medicine, General & Internal
Perrin E. Romine, Keith D. Eaton, Kelly G. Paulson, Rouba Hadi, Douglas S. Paauw
AMERICAN JOURNAL OF MEDICINE
(2019)
Article
Oncology
Perrin E. Romine, Renato G. Martins, Keith D. Eaton, Douglas E. Wood, Fatemeh Behnia, Bernardo H. L. Goulart, Michael S. Mulligan, Sarah G. Wallace, Elizabeth Kell, Julie E. Bauman, Shilpen A. Patel, Hubert J. Vesselle
Article
Biochemistry & Molecular Biology
Arnaud Augert, Emily Eastwood, Ali H. Ibrahim, Nan Wu, Eli Grunblatt, Ryan Basom, Denny Liggitt, Keith D. Eaton, Renato Martins, John T. Poirier, Charles M. Rudin, Francesca Milletti, Wei-Yi Cheng, Fiona Mack, David MacPherson
Article
Oncology
Cristina P. Rodriguez, Qian (Vicky) Wu, Jenna Voutsinas, Jonathan R. Fromm, Xiuyun Jiang, Venu G. Pillarisetty, Sylvia M. Lee, Rafael Santana-Davila, Bernardo Goulart, Christina S. Baik, Laura Q. M. Chow, Keith Eaton, Renato Martins
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Sara Bedrose, Kevin Charles Miller, Lina Altameemi, Mohamed S. Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D. Eaton, Jeffrey Thomas Yorio, Davey B. Daniel, Matthew Campbell, Keith C. Bible, Mabel Ryder, Ashish Chintakuntlawar, Mouhammed Amir Habra
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Cell Biology
Eli Grunblatt, Nan Wu, Huajia Zhang, Xiaoli Liu, Justin P. Norton, Yamini Ohol, Paul Leger, Joseph B. Hiatt, Emily C. Eastwood, Rhiana Thomas, Ali H. Ibrahim, Deshui Jia, Ryan Basom, Keith D. Eaton, Renato Martins, A. McGarry Houghton, David MacPherson
GENES & DEVELOPMENT
(2020)
Article
Oncology
Cristina M. Merkhofer, Keith D. Eaton, Renato G. Martins, Scott D. Ramsey, Bernardo H. L. Goulart
Summary: The impact of clinical trial participation on survival in cancer patients remains unclear. A study involving patients with advanced non-small cell lung cancer found that overall survival was similar between trial participants and nonparticipants, supporting the need for programs and policies to improve trial access.
CLINICAL LUNG CANCER
(2021)
Article
Oncology
Cristina Merkhofer, Shasank Chennupati, Qin Sun, Keith D. Eaton, Renato G. Martins, Scott D. Ramsey, Bernardo H. L. Goulart
Summary: The study showed that participation in clinical trials can lead to cost savings for healthcare payers, especially for patients with metastatic non-small-cell lung cancer. Specifically, participation in second-line trials can save healthcare payers $6,663 per month, with a more significant impact on Medicare patients. Further research is needed to explore the differences in cost savings between Medicare and commercial payers.
JCO ONCOLOGY PRACTICE
(2021)
Article
Oncology
Perrin E. Romine, Qin Sun, Catherine Fedorenko, Li Li, Mariel Tang, Keith D. Eaton, Bernardo H. L. Goulart, Renato G. Martins
Summary: The time from suspicion to diagnosis of non-small-cell lung cancer (NSCLC) has an impact on survival outcomes. This study aimed to evaluate the effect of the time from radiographic suspicion to histologic diagnosis on survival outcomes. The results showed that longer time to confirmation was associated with improved overall survival (OS) in all NSCLC patients. However, this association became non-significant when patients who died within 6 months of diagnosis were excluded.
JCO ONCOLOGY PRACTICE
(2022)
Article
Respiratory System
Viswam S. Nair, Keith Eaton, A. McGarry Houghton
Summary: Immune checkpoint inhibitor therapy may lead to exacerbation of COPD, but current literature does not report this occurrence. Patients experienced prolonged and severe COPD exacerbations without radiographic evidence of pneumonitis following treatment.
RESPIRATORY MEDICINE CASE REPORTS
(2021)
Article
Endocrinology & Metabolism
Nicole K. Zern, Keith D. Eaton, Mara Y. Roth
JOURNAL OF THE ENDOCRINE SOCIETY
(2019)